Literature DB >> 20043263

Deoxycholic acid and selenium metabolite methylselenol exert common and distinct effects on cell cycle, apoptosis, and MAP kinase pathway in HCT116 human colon cancer cells.

Huawei Zeng1, James H Botnen, Mary Briske-Anderson.   

Abstract

The cell growth inhibition induced by bile acid deoxycholic acid (DCA) may cause compensatory hyperproliferation of colonic epithelial cells and consequently increase colon cancer risk. On the other hand, there is increasing evidence for the efficacy of certain forms of selenium (Se) as anticancer nutrients. Methylselenol has been hypothesized to be a critical Se metabolite for anticancer activity in vivo. In this study, we demonstrated that both DCA (75-300 micromol/l) and submicromolar methylselenol inhibited colon cancer cell proliferation by up to 64% and 63%, respectively. In addition, DCA and methylselenol each increased colon cancer cell apoptosis rate by up to twofold. Cell cycle analyses revealed that DCA induced an increase in only the G1 fraction with a concomitant drop in G2 and S-phase; in contrast, methylselenol led to an increase in the G1 and G2 fractions with a concomitant drop only in the S-phase. Although both DCA and methylselenol significantly promoted apoptosis and inhibited cell growth, examination of mitogen-activated protein kinase (MAPK) pathway activation showed that DCA, but not methylselenol, induced SAPK/JNK1/2, p38 MAPK, ERK1/2 activation. Thus, our data provide, for the first time, the molecular basis for opposite effects of methylselenol and DCA on colon tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20043263     DOI: 10.1080/01635580903191551

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN: 0163-5581            Impact factor:   2.900


  9 in total

Review 1.  Differential regulation of EGFR-MAPK signaling by deoxycholic acid (DCA) and ursodeoxycholic acid (UDCA) in colon cancer.

Authors:  Sara M Centuori; Jesse D Martinez
Journal:  Dig Dis Sci       Date:  2014-06-11       Impact factor: 3.199

2.  Loss of organic anion transporting polypeptide 1a1 increases deoxycholic acid absorption in mice by increasing intestinal permeability.

Authors:  Youcai Zhang; Iván L Csanaky; Lois D Lehman-McKeeman; Curtis D Klaassen
Journal:  Toxicol Sci       Date:  2011-09-13       Impact factor: 4.849

Review 3.  Metabolism as a key to histone deacetylase inhibition.

Authors:  Praveen Rajendran; David E Williams; Emily Ho; Roderick H Dashwood
Journal:  Crit Rev Biochem Mol Biol       Date:  2011-04-05       Impact factor: 8.250

4.  Bile acids destabilise HIF-1α and promote anti-tumour phenotypes in cancer cell models.

Authors:  J P Phelan; F J Reen; N Dunphy; R O'Connor; F O'Gara
Journal:  BMC Cancer       Date:  2016-07-14       Impact factor: 4.430

5.  Novel library of selenocompounds as kinase modulators.

Authors:  Daniel Plano; Elena Ibáñez; Alfonso Calvo; Juan Antonio Palop; Carmen Sanmartín
Journal:  Molecules       Date:  2011-07-27       Impact factor: 4.411

6.  Biodegradable, bile salt microparticles for localized fat dissolution.

Authors:  Hanieh Safari; Nicholas Kaczorowski; Michael L Felder; Emma R Brannon; Mita Varghese; Kanakadurga Singer; Omolola Eniola-Adefeso
Journal:  Sci Adv       Date:  2020-12-04       Impact factor: 14.136

Review 7.  New Insights into Bile Acids Related Signaling Pathways in the Onset of Colorectal Cancer.

Authors:  Cristiana Caliceti; Angela Punzo; Alessia Silla; Patrizia Simoni; Giulia Roda; Silvana Hrelia
Journal:  Nutrients       Date:  2022-07-20       Impact factor: 6.706

Review 8.  Three measurable and modifiable enteric microbial biotransformations relevant to cancer prevention and treatment.

Authors:  Gregory A Plotnikoff
Journal:  Glob Adv Health Med       Date:  2014-05

9.  Scutellariae Radix and Coptidis Rhizoma Improve Glucose and Lipid Metabolism in T2DM Rats via Regulation of the Metabolic Profiling and MAPK/PI3K/Akt Signaling Pathway.

Authors:  Xiang Cui; Da-Wei Qian; Shu Jiang; Er-Xin Shang; Zhen-Hua Zhu; Jin-Ao Duan
Journal:  Int J Mol Sci       Date:  2018-11-18       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.